Atrium Therapeutics financials
$8.420.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $18.8M | $10.9M | $9.6M | $9.2M | $9.3M | $6.8M |
| Gross profit | $18.8M | $10.9M | $9.6M | $9.2M | $9.3M | $6.8M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$745.9M | -$378.9M | -$235.6M | -$178.9M | -$118.1M | -$44.3M |
| Net income | -$684.6M | -$322.3M | -$212.2M | -$174.0M | -$118.0M | -$44.4M |
| Net margin | −3650.4% | −2957.7% | −2219.9% | −1886.3% | −1265.4% | −653.5% |
| Diluted EPS | $-4.97 | $-2.89 | $-2.91 | $-3.34 | $-2.85 | $-2.05 |
| EBITDA | -$741.8M | -$376.2M | -$233.5M | -$177.5M | -$116.7M | -$43.9M |
| Operating cash flow | -$650.4M | -$300.9M | -$119.1M | -$136.3M | -$94.8M | -$37.1M |
| Free cash flow | -$663.8M | -$307.9M | -$123.3M | -$139.1M | -$98.6M | -$38.2M |
| Diluted shares | 137.7M | 111.6M | 73.0M | 52.2M | 41.4M | 21.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $382.5M | $219.9M | $185.1M | $340.4M | $320.4M | $321.5M |
| Short-term investments | $1.31B | $1.28B | $410.3M | $270.3M | $85.1M | $6.7M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $1.96B | $1.56B | $628.6M | $638.8M | $427.6M | $333.9M |
| Total liabilities | $269.4M | $138.9M | $127.8M | $60.7M | $46.1M | $27.7M |
| Shareholders' equity | $1.69B | $1.42B | $500.8M | $578.1M | $381.4M | $306.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology